CANCER AND LEUKEMIA GROUP B

杜克医疗中心目前正在完成其第一个5年赠款周期 作为癌症和白血病B组(CALGB)的成员。在这段时间里 在此期间，杜克大学一直是 总体患者收益，并一直是患者领域的领先机构 主要成员机构的应计费用。杜克大学目前正在开发一种 将导致患者数量大幅增加的附属计划 应计费用。院内和院外的临床试验是协调的 通过杜克大学的中央礼宾室。这个办公室提供核心 为一大群人提供行政支持和质量保证 协调临床试验的研究护士和数据经理 疾病和形态的具体依据。这个组织结构是 通过与CALGB生物统计的密切互动进一步加强 和数据管理中心在杜克大学，由斯蒂芬博士指导 他也是杜克癌症中心的生物统计学主任。 从科学上讲，杜克大学有活跃的干部成员负责所有的疾病和 与情态相关的CALGB委员会。目前，杜克大学的12名调查人员 参与正在进行或计划中的CALGB试验。杜克大学调查员 担任悬而未决的随机第三阶段试验的研究主席 AML<60的患者，剂量的随机III期试验 集落刺激因子支持下的CHOP强化化疗 大剂量的主要国家随机试验--非霍奇金淋巴瘤 辅助性自体骨髓支持化疗 乳腺癌的治疗，紫杉醇在乳房III期的待定试验 癌症患者，多项呼吸道癌和骨癌的试验。在……里面 此外，杜克大学一直是药理学第一阶段试验的中心 和实验治疗学，并一直是 心理肿瘤学。多通道。还提供了以下支持 外科肿瘤学、放射肿瘤学、 病理学及相关科学。此外，杜克大学一直是 少数群体患者应计和高优先级试验的贡献者。区域 杜克大学调查人员在CALGB内的下一笔拨款 周期将涉及癌症控制、癌症治疗成本分析和 老年肿瘤学。作为CALGB活动的领先机构 在最初的赠款周期中，杜克大学期待着资金支持 与我们当前和预期的患者收益和 在下一个赠款周期中科学地参与CALGB试验。

Duke Medical Center is currently completing its first 5 year grant cycle as a member of Cancer and Leukemia Group B (CALGB). During this time period, Duke has consistently been one of the top five institutions in overall patient accrual, and has been the leading institution in patient accrual from a main member institution. Duke is currently developing an affiliate program which will lead to a substantial increase in patient accrual. Both intramural and extramural clinical trials are coordinated through a central protocol office at Duke. This office provides core administrative support and quality assurance for a large group of research nurses and data managers who coordinate clinical trials on a disease and modality specific basis. This organizational structure is further strengthened by close interaction with the CALGB biostatistics and data management center at Duke under the direction of Dr. Stephen George, who is also Director of Biostatistics for the Duke Cancer Center. Scientifically, Duke has active cadre members on all the disease and modality related CALGB committees. Currently, 12 investigators at Duke are involved in ongoing or planned CALGB trials. Duke investigators serve as study chairs on the pending randomized Phase III trial for patients with AML less than 60, the randomized Phase III trial of dose intensified CHOPE chemotherapy with colony stimulating factor support in non Hodgkins lymphoma, the major national randomized trial of high dose chemotherapy with autologous bone marrow support in the adjuvant treatment of breast cancer, the pending trial of Taxol in StageIII breast cancer patients, a number of respiratory cancer and GU cancer trials. In addition, Duke has been a center for Phase I trials for the pharmacology and experimental therapeutics and has been a leading center for psycho-oncology. Multi modality. support has also been provided by active participation from surgical oncology, radiation oncology, Pathology and correlative sciences. In addition, Duke has been a major contributor to minority patient accrual and high priority trials. Areas of expansion by Duke investigators within the CALGB over the next grant cycle will involve cancer control, cancer treatment cost analysis, and gero-oncology. As a leading institution in CALGB activities during our initial grant cycle, Duke is looking forward to funding support appropriate to our current and anticipated level of patient accrual and scientific involvement in CALGB trials during the next grant cycle.